Triptolide injection reduces Alzheimer's disease‐like pathology in mice
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Triptolide is an epoxidized diterpene lactone isolated from Tripterygium wilfordii. Studies have shown that triptolide exerts organ‐protective effects. However, it remains unknown whether triptolide improves Alzheimer's disease (AD)‐like presentations. Thirty healthy 8‐week‐old male C57BL/6J mice were randomly divided into control (n = 10), model (n = 10), and triptolide (n = 10) groups. Amyloid‐β (Aβ)42 was injected bilaterally into the ventricles of mice in the model group. Triptolide was injected intraperitoneally daily after injecting Aβ42 (a total of 30 days) in the triptolide group. Learning and memory were tested using the Morris water maze test. The deposition of Aβ42 in the hippocampus was detected using immunohistochemical staining. In the hippocampus, three synaptic‐associated proteins—gephyrin, collybistin, and GABRA1—were detected by western blotting. Furthermore, we used ELISA to detect proinflammatory cytokines, including TNF‐α and IL‐1β, in the blood and hippocampus. Moreover, superoxide dismutase (SOD), malondialdehyde (MDA), and GSH levels were measured using the corresponding kits. We found that triptolide improved spatial learning and memory in AD‐like mice. Additionally, triptolide maintained the expression of gephyrin, collybistin, and GABRA1 and reduced Aβ in these mice. Additionally, triptolide reduced the expression of inflammatory cytokines and decreased oxidative damage in AD‐like mice. Our study suggests that triptolide attenuates AD‐like changes in the mouse brain.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Triptolide injection reduces Alzheimer's disease‐like pathology in mice
- Date Crossref
- 07/02/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hubei University of Medicine Department of Neurology Sinopharm Dongfeng General Hospital pays non établi dans la noticeUniversité ou école supérieure
-
China National Pharmaceutical Group Corporation (China) pays non établi dans la noticeEntreprise
-
Dongfeng General Hospital Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Jinzhou Medical University Department of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
University of Virginia Department of Anesthesiology pays non établi dans la noticeUniversité ou école supérieure
Department of Neurology Sinopharm Dongfeng General Hospital — Hubei University of Medicine, China National Pharmaceutical Group Corporation (China) et Department of Neurology — Dongfeng General Hospital, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.